Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Building bone to reverse osteoporosis and repair fractures.

Khosla S, Westendorf JJ, Oursler MJ.

J Clin Invest. 2008 Feb;118(2):421-8. doi: 10.1172/JCI33612. Review.

2.

Skeletal remodeling in health and disease.

Zaidi M.

Nat Med. 2007 Jul;13(7):791-801. Review.

PMID:
17618270
3.
4.

NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF.

Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY.

Nat Med. 2007 Jan;13(1):62-9. Epub 2006 Dec 10.

PMID:
17159986
5.

Estrogen receptor ligands in the control of pathogenic inflammation.

Harnish DC.

Curr Opin Investig Drugs. 2006 Nov;7(11):997-1001. Review.

PMID:
17117588
6.

Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.

Pearse RN.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6274s-6278s. Review.

7.

Estrogen deficiency and bone loss: an inflammatory tale.

Weitzmann MN, Pacifici R.

J Clin Invest. 2006 May;116(5):1186-94. Review.

8.

Pathogenesis of osteoporosis: concepts, conflicts, and prospects.

Raisz LG.

J Clin Invest. 2005 Dec;115(12):3318-25. Review.

9.

The role of the immune system in the pathophysiology of osteoporosis.

Clowes JA, Riggs BL, Khosla S.

Immunol Rev. 2005 Dec;208:207-27. Review.

PMID:
16313351
10.

Pathophysiology of age-related bone loss and osteoporosis.

Khosla S, Riggs BL.

Endocrinol Metab Clin North Am. 2005 Dec;34(4):1015-30, xi. Review. No abstract available.

PMID:
16310636
11.

Visualizing levels of osteoblast differentiation by a two-color promoter-GFP strategy: Type I collagen-GFPcyan and osteocalcin-GFPtpz.

Bilic-Curcic I, Kronenberg M, Jiang X, Bellizzi J, Mina M, Marijanovic I, Gardiner EM, Rowe DW.

Genesis. 2005 Oct;43(2):87-98.

PMID:
16149065
12.

I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss.

Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu LC, Cao Y, Schett G, Wagner EF, Karin M.

J Exp Med. 2005 May 16;201(10):1677-87.

13.

Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation.

Yamashita M, Ying SX, Zhang GM, Li C, Cheng SY, Deng CX, Zhang YE.

Cell. 2005 Apr 8;121(1):101-13.

14.

Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair.

Zelzer E, Olsen BR.

Curr Top Dev Biol. 2005;65:169-87. Review. No abstract available.

PMID:
15642383
15.

The Fos-related antigen Fra-1 is an activator of bone matrix formation.

Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, Amling M, Wagner EF.

EMBO J. 2004 Jul 21;23(14):2789-99. Epub 2004 Jul 1.

16.

Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.

Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S.

Nat Med. 2004 Jun;10(6):617-24. Epub 2004 May 23.

PMID:
15156202
17.

Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors.

Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS.

Crit Rev Eukaryot Gene Expr. 2004;14(1-2):1-41. Review.

PMID:
15104525
18.

Twist genes regulate Runx2 and bone formation.

Kronenberg HM.

Dev Cell. 2004 Mar;6(3):317-8.

20.

Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress.

Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S.

Cell. 2003 Nov 26;115(5):565-76.

Items per page

Supplemental Content

Write to the Help Desk